KIMS774.00

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹30,960 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations652.5605.8633.8688.4777.3772.4796.9871.6960.7997.71,074.61,179.5
Other Income2.93.33.84.65.017.84.57.14.25.29.716.4
Total Income655.4609.1637.6693.0782.3790.2801.4878.7964.91,002.91,084.31,195.9
Expenses
+ Purchases of Stock-in-Trade142.5124.5135.2144.8156.6169.8169.2191.7203.5211.2235.4260.9
+ Changes in Inventories-2.11.1-0.9-2.2-1.1-8.0-2.1-7.7-8.3-14.3-2.6-16.2
+ Employee Benefit Expense105.7104.3108.5118.6119.2127.5134.1151.0174.5176.3179.9212.6
+ Finance Costs8.912.416.417.919.925.726.732.645.056.868.183.4
+ Depreciation & Amortisation32.635.446.339.041.044.752.653.466.178.785.0100.8
+ Other Expenses229.1228.9232.0247.8284.5295.9297.7344.0387.0425.6455.4498.8
Total Expenses516.7506.5537.5565.9620.1655.6678.2765.0867.8934.31,021.21,140.3
EBITDA177.3147.1159.0179.4218.1187.2198.0192.6204.0198.9206.5223.4
EBIT144.7111.7112.7140.4177.1142.5145.4139.2137.9120.2121.5122.6
Profit
PBT before Exceptional Items138.6102.6100.1127.1162.2134.6123.2113.797.168.663.155.6
+ Exceptional Items-0.00.00.00.00.00.010.80.0-0.30.0-10.90.0
Pretax Income138.6102.6100.1127.1162.2134.6134.0113.796.868.652.255.6
+ Current Tax37.221.928.733.845.035.335.732.437.733.134.833.8
+ Deferred Tax0.24.0-0.2-1.9-3.56.8-7.8-3.7-12.9-16.4-13.1-14.6
Tax Expense37.325.928.531.941.542.127.928.724.816.721.719.2
+ Share of Associates & JVs0.0-0.1-0.10.00.00.00.00.00.00.02.61.0
Net Income101.376.671.595.2120.792.5106.185.072.051.933.137.4
+ Net Income — Continuing Ops101.376.771.695.2120.792.5106.185.072.051.930.536.4
+ Other Comprehensive Income0.20.2-0.30.1-2.3-0.90.8-0.50.30.00.40.0
Total Comprehensive Income101.576.871.295.3118.491.6106.984.572.351.933.537.4
Net Income to Common92.271.865.586.6107.4101.878.667.153.442.541.5
Minority Interest9.34.76.08.613.34.36.45.2-1.5-9.4-4.1
Per Share
Basic EPS11.508.988.1810.822.682.222.541.961.671.331.061.04
Diluted EPS11.508.988.1810.822.682.222.541.961.671.331.061.04
Other Comprehensive Income — detail
+ Other Comprehensive Income0.8-0.50.30.00.40.0
+ Tax on Items NOT to be Reclassified-1.10.6-0.40.0-0.40.0
+ Tax on Items NOT to be Reclassified — alt tag-0.3-0.20.4-0.13.11.2
+ Tax on Items to be Reclassified0.3-0.10.10.00.00.0
+ Tax on Items to be Reclassified — alt tag0.10.0-0.10.0-0.8-0.3
Comprehensive Income — Owners of Parent0.272.165.20.1105.488.0102.578.20.20.042.80.0
Comprehensive Income — Non-controlling Interests0.04.76.00.013.03.64.46.30.10.0-9.30.0
Per Share — as-filed variants
Basic EPS — Continuing Operations11.508.988.1810.822.682.222.541.961.671.331.061.04
Diluted EPS — Continuing Operations11.508.988.1810.822.682.222.541.961.671.331.061.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit512.1480.3499.5545.8621.8610.6629.8687.6765.5800.8841.8934.8
Gross Margin %78.4879.2778.8179.2979.9979.0579.0378.8979.6880.2678.3479.25
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)138.6102.6100.1127.1162.2134.6123.2113.797.168.663.155.6
− Exceptional Items (reconciliation)-0.00.00.00.00.00.010.80.0-0.30.0-10.90.0
Net Income Adj (tax-effected)101.376.671.595.2120.792.597.585.072.251.939.537.4
EPS Adj11.508.988.1810.822.682.222.341.961.681.331.261.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.002.002.002.002.002.0021,696.002.002.00
Paid Up Equity Capital80.080.080.080.080.080.080.080.080.080.080.084.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.